Gentamicin Dosing in Dialysis Patients
For adults on intermittent hemodialysis, administer gentamicin 1-1.7 mg/kg (up to 2 mg/kg in children) immediately after each dialysis session 1. This post-dialysis timing is the FDA-approved standard and is endorsed by IDSA guidelines for catheter-related infections 2.
Hemodialysis Dosing Strategy
Standard Intermittent Hemodialysis (3x/week)
Post-dialysis administration is the established approach:
- Adults: 1-1.7 mg/kg after each dialysis session, depending on infection severity 1
- Children: 2 mg/kg after each dialysis session 1
- Rationale: An 8-hour hemodialysis removes approximately 50% of serum gentamicin 1
The FDA label explicitly states this dosing for patients with renal failure undergoing hemodialysis 1. The IDSA guideline for catheter-related bloodstream infections in hemodialysis patients recommends 1 mg/kg (not exceeding 100 mg) after each dialysis session 2.
Alternative Consideration: Pre-dialysis Dosing
Recent pharmacokinetic modeling suggests pre-dialysis dosing may achieve better target attainment for certain PK/PD goals:
- Non-septic patients: 5 mg/kg given 1-2 hours before dialysis achieved 100% target attainment for Cmax >8 mg/L 3
- Septic patients: 6 mg/kg given 1 hour before dialysis showed improved efficacy targets 3
- This approach may be considered when MIC = 1-4 mg/L, using 2-8 mg/kg before dialysis with at least 96 hours between doses 4
Critical caveat: Pre-dialysis dosing contradicts FDA labeling and established guidelines. While pharmacokinetic simulations show promise 3, 4, this remains investigational and requires therapeutic drug monitoring.
Short-Daily Hemodialysis (SDHD)
For patients on daily or near-daily dialysis:
- Pre-dialysis every-other-day dosing appears more effective and less toxic than post-dialysis daily dosing 5
- Gentamicin dialytic clearance is substantially higher (134 ml/min) with SDHD compared to conventional schedules 5
- Consider 2 mg/kg pre-dialysis on alternate dialysis days 5
Peritoneal Dialysis
Intraperitoneal administration is preferred for treating peritonitis:
- Concentration: 15 mg/L in dialysate fluid 6, 7
- Volume: 0.7 L/m² per cycle 7
- Serum concentrations reach approximately 25-68% of dialysate concentrations 7
- Peritoneal clearance averages 4.0 ml/min/m² (range 1.2-7.0) 7
For systemic infections in peritoneal dialysis patients, dosing guidance is limited and requires individualized therapeutic drug monitoring.
Continuous Renal Replacement Therapy (CRRT)
The evidence does not provide specific CRRT dosing recommendations. CRRT patients differ substantially from intermittent hemodialysis patients in medication patterns and clearance 8. Therapeutic drug monitoring is essential as standard dosing guidance is lacking for this population 8.
Monitoring Requirements
Therapeutic drug monitoring is critical in all dialysis modalities:
- Target peak: 4-6 mcg/mL for conventional dosing; 8-12 mcg/mL for once-daily dosing in neonates 1
- Target trough: <2 mcg/mL to minimize nephrotoxicity and ototoxicity 1
- Peak levels >12 mcg/mL should be avoided 1
- Measure peak 30-60 minutes after IM injection or at end of IV infusion 1
- Measure trough just before next dose 1
Key Clinical Pitfalls
- Do not use standard renal impairment dosing tables for dialysis patients—they underestimate drug removal 1
- Dialysis method matters: Short-daily hemodialysis removes significantly more drug than conventional schedules 5
- Anuric vs. non-anuric status affects pharmacokinetics in peritoneal dialysis patients 6
- The "standard" 1 mg/kg post-dialysis dose may be insufficient for organisms with MIC ≥1 mg/L 4
- Pediatric patients require higher weight-based doses (2 mg/kg vs. 1-1.7 mg/kg in adults) 1